Access practice tools, as well as industry leading news, customizable alerts, dockets, and primary content, including a comprehensive collection of case law, dockets, and regulations. Leverage...
By Tony Dutra
Nov. 14 — Purdue Pharma L.P. lost its last chance Nov. 14 to use patent protection to stall certain generic versions of its best-selling painkiller, OxyContin.
The U.S. Supreme Court rejected two petitions for review of U.S. Court of Appeals for the Federal Circuit rulings. The appeals court held that three Purdue patents on a less toxic formulation known as low-ABUK oxycodone were invalid as obvious, and that Grünenthal GmbH’s patent on making OxyContin resistant to abuse was not novel. Purdue licenses Grünenthal’s patent.
Amneal Pharmaceuticals LLC, Epic Pharma LLC, Mylan Pharmaceuticals Inc. and Teva Pharmaceuticals USA Inc. have announced plans to introduce generic low-ABUK or abuse-resistant oxycodone.
Purdue’s U.S. Patent Nos. 7,674,799, 7,674,800 and 7,683,072 claim an improved formulation with reduced 14-hydroxycodeinone—an alpha, beta unsaturated ketone (ABUK) determined by the Food and Drug Administration to be toxic to human DNA. According to Purdue’s petition, scientists had tried but failed to achieve the reduction until Purdue and Rhodes Technologies discovered an agent that was reintroducing 14-hydroxycodeinone late in the manufacturing process.
The Federal Circuit ruled that an inventor can get a method patent based on being the first to recognize a problem and apply the remedy, but here Purdue claimed the end product. Purdue Pharma LP v. Epic Pharma, LLC, 811 F.3d 1345, 117 U.S.P.Q.2d 1733 (Fed. Cir. 2016).
Grünenthal’s U.S. Patent No. 8,114,383 claims “thermoforming” technology that makes the pills so hard it prevents crushing them and injecting the powder to get an opioid high.
The Federal Circuit said that the technology was previously described as a solution for “a broader group of analgesics.” The required hardness is an “inherited” quality when applying the solution to an opioid, the court said.
Gregory A. Castanias of Jones Day, Washington, represented Purdue. Charles E. Lipsey of Finnegan, Henderson, Farabow, Garrett & Dunner LLP, Reston, Va., represented Grünenthal. Fried, Frank, Harris, Shriver & Jacobson LLP, New York, filed an amicus brief urging review, on behalf of Professor Richard E. Kouri of North Carolina State University.
None of the generic drug makers filed a response in opposition. The high court’s docket identified Rakoczy Molino Mazzochi Siwik LLP, Chicago, as counsel of record for Mylan, and Carlson, Caspers, Vandenburgh, Lindquist & Schuman P.A., Minneapolis, as counsel for Teva.
Purdue Pharma L.P. v. Epic Pharma, LLC , U.S., No. 16-289, review denied 11/14/16 . Grunenthal GmbH v. Teva Pharms. USA, Inc. , U.S., No. 16-296, review denied 11/14/16 .
Copyright © 2016 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)